GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pucolentimab   Click here for help

GtoPdb Ligand ID: 13886

Synonyms: HX-008 | HX008 | Puyouheng®
Approved drug
pucolentimab is an approved drug
Compound class: Antibody
Comment: Pucolentimab (formerly HX008) is an anti-PD-1 immune checkpoint inhibitor monoclonal antibody [2]. It blocks interactions between PD-1 and its ligands PD-L1 and PD-L2, and this reactivates a T cell-mediated antitumour response. Pucolentimab has negligible binding to Fc-gamma receptors (FcγRIIIa) or or C1q and therefore exhibits minimal ADCC and CDC activity [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Pucolentimab was granted first approval in China for the treatment of patients with unresectable or metastatic solid tumours with high microsatellite instability or mismatch repair defects, including advanced colorectal cancers [1]. Approval was later expanded to include treatment of unresectable/metastatic melanomas that are unresponsive to previous systemic therapy.